The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

A new clinical trial led by the Jaeb Center for Health Research has shown that automated insulin delivery (AID) systems can significantly improve blood sugar control in adults with type 2 diabetes who ...

Dexcom previews new data for 15-day glucose monitor Dexcom shared the first data for its 15-day ... Tandem found that people ...

If you have diabetes, a continuous glucose monitor (CGM ... including the Dexcom G7 or its earlier version, the Dexcom G6. What part of Medicare covers the Dexcom G7? Generally, Medicare Part ...

will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear’s previously FDA cleared cardiovascular biomarkers. The continuous ...

including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom’s handling last year of a deficiency ...